Toft Group Completes Chief Medical Officer Search for Fate Therapeutics, Inc. (NASDAQ:FATE) in San Diego, CA


Fate Therapeutics, Inc. (NASDAQ:FATE), a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, today announced that Chris M. Storgard, M.D. has joined the Company as its Chief Medical Officer. Dr. Storgard is an experienced drug development clinician with a proven history of advancing early stage programs through clinical development and product commercialization. As CMO, he will lead the design and execution of the Company's clinical trials for its programmed cellular immunotherapies.

Robin Toft, Chief Executive Officer of Toft Group, Inc. said: “Fate Therapeutics is an exciting company with an incredibly strong leadership team. We expect Dr. Storgard will add great value to the organization, ultimately helping Fate bring their novel products to market to improve the lives of patients with cancer and autoimmune disorders.”

Dr. Storgard has more than 20 years of experience in clinical drug development, most recently serving as an integral member of the executive team at Ardea Biosciences, a member of the AstraZeneca Group. As Vice President of Clinical Research and Development at Ardea, Dr. Storgard led the ZURAMPIC® global clinical program to successful U.S. and European regulatory approvals.

"I am excited to be joining the team at Fate Therapeutics at this pivotal point in the Company's evolution as we seek to rapidly and efficiently drive the clinical development of multiple ground-breaking immunotherapies," said Dr. Storgard. "It is a privilege to provide strategic and operational leadership to guide the advancement of novel therapies with the potential to address significant unmet medical needs and transform outcomes for millions of patients with cancer and autoimmune disorders."

Before joining Ardea in 2011, Dr. Storgard held senior positions in drug development and medical affairs at Prometheus Laboratories, Biogen Idec, and Amgen, where he focused on biologic and small molecule development programs within the inflammation and oncology teams. Dr. Storgard holds his M.D. from the University of Saskatchewan. He also completed a fellowship in Rheumatology at Scripps Clinic and Research Center, and served as Senior Associate Consultant, Division of Rheumatology, and Assistant Professor and Member of the Molecular Medicine Program at the Mayo School of Medicine, Mayo Clinic in Minnesota.

About Toft Group Executive Search

Toft Group Executive Search is “Changing the Future of Medicine, One Relationship at a Time” and we take pride in the fact that our work helps our clients accelerate getting novel products to market. We are a global retained executive search firm that is 100% dedicated to life sciences & healthcare industries. Our customers include biotech, pharmaceutical, medical device, digital health, and diagnostic companies. With offices in San Francisco, San Diego, and Boston, we assist a wide range of local, national and international companies - from venture backed start-ups to Fortune 500 corporations.

About Fate Therapeutics, Inc.

Fate Therapeutics is a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders. The Company's cell therapy pipeline is comprised of immuno-oncology programs, including off-the-shelf NK- and T-cell cancer immunotherapies derived from engineered induced pluripotent cells, and immuno-regulatory programs, including hematopoietic cell immunotherapies for protecting the immune system of patients undergoing hematopoietic cell transplantation and for suppressing autoimmunity. Its adoptive cell therapy programs are based on the Company's novel ex vivo cell programming approach, which it applies to modulate the therapeutic function and direct the fate of immune cells. Fate Therapeutics is headquartered in San Diego, CA.